Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive biomarker study in Crohn's disease during biologic treatment
jRCT1031190056Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of adalimumab, infliximab and ustekinumab in Crohn's disease (3 cohorts), sponsored by EA Pharma Co., Ltd. Primary endpoints: Immune cell fractionation ratio and Correlation between flow cytometry and DNA methylation analysis. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT1031190056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031190056.